预约演示
更新于：2025-07-23
Cagrilintide
更新于：2025-07-23
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 720102737
来源: *****
关联
34
项与 Cagrilintide 相关的临床试验NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity
NCT06719011
A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.
NCT06716307
Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity
100 项与 Cagrilintide 相关的临床结果
登录后查看更多信息
100 项与 Cagrilintide 相关的转化医学
登录后查看更多信息
100 项与 Cagrilintide 相关的专利（医药）
登录后查看更多信息
61
项与 Cagrilintide 相关的文献（医药）2025-10-01LIFE SCIENCES
Characterization of 0839 – A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide
Article
作者: Kuhre, Rune Ehrenreich ; Gabery, Sanaz ; Raun, Kirsten ; Kruse, Thomas ; Glendorf, Tine ; Pedersen, Kent ; Ballarin-Gonzalez, Borja
Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide. Structurally, 0839 shares 95 % sequence homology with 0833 and contains an identical acylation sidechain. Acute administration of 0839 and 0833 to normal weight rats' dose-dependently reduced food intake to a similar degree. Sub-chronically, 0839 and 0833 had comparable small and transient reducing effects on food intake and body weight in DIO mice, with similar additional add-on effects on top of semaglutide. In DIO rats, sub-chronic administration of 0833 and 0839 profoundly reduced food intake and body weight, and both potentiated semaglutide's effects on food intake and body weight to an equal extended. Both compounds mainly reduced body weight by fat mass reduction and equally improved metabolic parameters. Notably, 0839 is available through Novo Nordisk Compound Sharing, enabling advancement of mode-of-action studies in mice and rats whilst usage of cagrilintide and other amylin analogues in clinical development are restricted due to pharmacovigilance rules.
2025-08-01EBioMedicine
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Article
作者: Lundh, Sofia ; Hassan, Shad ; Raun, Kirsten ; Secher, Anna ; Carvas, Alexandra Oliveira ; Pers, Tune ; Coester, Bernd ; Lutz, Thomas A ; Le Foll, Christelle ; Lommi, Greta ; Leuthardt, Andrea ; Kulka, Patricia
BACKGROUND:
Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 or 3 (RAMP1-3).
METHODS:
We investigated the role of amylin 1 and 3 (AMY1R, AMY3R) receptors in modulating the pharmacological effects of the dual amylin-calcitonin receptor agonists, cagrilintide and salmon calcitonin (sCT), in RAMP1/3 knockout (KO) mice. Male wild-type (WT) and KO littermate mice were fed high-fat diet for 23 weeks prior to the 3-week treatment period with vehicle, 150 nmol/kg sCT or 3 nmol/kg cagrilintide (subcutaneously, SID).
FINDINGS:
Body weight loss was observed in WT cagrilintide-treated mice (-3.4 ± 0.51 g, P < 0.005; n = 8/group), whereas sCT rather increased it (0.60 ± 0.38 g, P < 0.01; n = 8/group). The absence of RAMP1 and RAMP3 impeded cagrilintide's potency but improved sCT's efficacy on weight loss. Cagrilintide and sCT both decreased food intake during the first few days of treatment in WT mice only (Day 1: vehicle 2.7 ± 0.2 g; cagrilintide 1.2 ± 0.1 g, P < 0.0001; sCT 1.5 ± 0.2 g, P < 0.0021; n = 7-8/group). Both peptides activated cFos signal in neurons of the dorsal vagal complex (DVC) and lateral parabrachial nucleus (LPBN) of WT mice while AP cFos signal was decreased in cagrilintide-treated RAMP1/3 KO mice by 57% compared to WT cagrilintide-injected mice (P < 0.001, n = 5-6/group). Differential gene expression was analysed in the DVC, LPBN and mediobasal hypothalamic area of WT and RAMP1/3 KO mice. After 3 weeks of treatment, neither sCT nor cagrilintide significantly altered gene expression in the DVC or LPBN in WT mice. However, mRNA bulk sequencing points to a role of RAMP1/3 in synaptic function and receptor trafficking.
INTERPRETATION:
Altogether, these results demonstrate the dependency of cagrilintide on AMY1R and AMY3R to lower body weight.
FUNDING:
This work was supported by an investigator led Novo Nordisk Consortium grant, Swiss National Foundation and the University of Zurich.
2025-06-22NEW ENGLAND JOURNAL OF MEDICINE
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Article
作者: Osorto Contreras, Cynthia Karenina ; Zeuthen, Niels ; Rubino, Domenica ; Winning Lehmann, Eva ; Blüher, Matthias ; Wadden, Thomas ; Wilding, John P H ; Garvey, W Timothy ; Pietiläinen, Kirsi H ; Sbraccia, Paolo ; Davies, Melanie J
BACKGROUND:
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.
METHODS:
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. Participants were randomly assigned in a ratio of 21:3:3:7 to receive the combination of semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg, semaglutide alone at a dose of 2.4 mg, cagrilintide alone at a dose of 2.4 mg, or placebo, plus lifestyle interventions for all groups. The coprimary end points were the relative change in body weight and a reduction of 5% or more in body weight from baseline to week 68 with cagrilintide-semaglutide as compared with placebo. Body-weight reductions of 20% or more, 25% or more, and 30% or more were assessed as confirmatory secondary end points. Effect estimates were assessed with the treatment-policy estimand (consistent with the intention-to-treat principle). Safety was assessed.
RESULTS:
A total of 3417 participants underwent randomization, with 2108 assigned to receive cagrilintide-semaglutide, 302 to receive semaglutide, 302 to receive cagrilintide, and 705 to receive placebo. The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001). Participants receiving cagrilintide-semaglutide were more likely than those receiving placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more, and 30% or more (P<0.001 for all comparisons). Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity.
CONCLUSIONS:
Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. (Funded by Novo Nordisk; REDEFINE 1 ClinicalTrials.gov number, NCT05567796.).
100 项与 Cagrilintide 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 临床3期 | 美国 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 中国 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 日本 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 阿根廷 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 巴西 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 保加利亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 克罗地亚 | 2023-09-27 | |
| 2型糖尿病 | 临床3期 | 捷克 | 2023-09-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 3,417 | Cagrilintide-Semaglutide | 鹹簾遞廠廠窪構遞鏇觸(鏇網鬱醖憲鑰積艱願壓) = Gastrointestinal adverse events (affecting 79.6% in the cagrilintide-semaglutide group and 39.9% in the placebo group), including nausea, vomiting, diarrhea, constipation, or abdominal pain, were mainly transient and mild-to-moderate in severity 壓鬱鹽觸壓鑰願淵淵顧 (築齋餘壓製範顧繭製糧 ) | 积极 | 2025-06-22 | |
N/A | - | - | Cagrilintide 3 nmol/kg | 獵鹽夢選膚艱憲糧蓋選(艱製蓋餘窪艱壓糧鑰糧) = 鑰願築憲鹽顧鏇艱願獵 築鑰鬱衊鑰鏇鬱觸窪膚 (餘網簾構齋膚簾蓋襯顧 ) | - | 2024-06-14 | |
Cagrilintide 10 nmol/kg | 獵鹽夢選膚艱憲糧蓋選(艱製蓋餘窪艱壓糧鑰糧) = 壓構構壓憲壓鬱顧衊鑰 築鑰鬱衊鑰鏇鬱觸窪膚 (餘網簾構齋膚簾蓋襯顧 ) | ||||||
临床2期 | 92 | (Cagrilintide 2.4 mg + Semaglutide 2.4 mg) | 窪蓋齋繭憲鏇製艱網鬱(簾鑰襯鏇鬱廠顧遞顧顧) = 簾壓構壓積網壓蓋壓鏇 壓齋鏇艱廠鑰糧鏇淵顧 (觸範餘窪網觸選淵襯壓, 0.9) 更多 | - | 2023-07-27 | ||
(Semaglutide 2.4 mg + Placebo (Cagrilintide)) | 窪蓋齋繭憲鏇製艱網鬱(簾鑰襯鏇鬱廠顧遞顧顧) = 繭艱鑰夢繭襯簾積簾顧 壓齋鏇艱廠鑰糧鏇淵顧 (觸範餘窪網觸選淵襯壓, 1.0) 更多 | ||||||
临床2期 | 706 | 範廠顧顧醖鏇遞觸網憲(觸廠壓廠鬱築壓蓋願鑰) = 壓遞鏇襯壓淵鹽糧網鑰 鹹蓋衊艱繭鏇壓構壓憲 (壓齋築襯壓廠淵選築顧, 5.6) 更多 | - | 2023-07-18 | |||
临床2期 | 92 | 鬱鏇選壓淵醖觸餘鹽壓(獵範鬱構醖簾鏇製鹹築): estimated treatment difference = -20.2 (95% CI, -39.8 ~ -0.7), P-Value = 0.04 | - | 2023-06-23 | |||
临床1期 | - | 96 | 鏇獵觸顧衊醖願淵築鹹(艱淵衊淵選範積膚衊製) = 鹽夢糧選蓋鏇壓觸鹹積 選餘願廠範齋繭簾餘襯 (範餘願願膚齋網餘窪憲 ) 更多 | - | 2021-04-22 | ||
鏇獵觸顧衊醖願淵築鹹(艱淵衊淵選範積膚衊製) = 範網鏇鏇遞鏇繭鹽鹹鏇 選餘願廠範齋繭簾餘襯 (範餘願願膚齋網餘窪憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用